Olanzapine is an atypical antipsychotic, FDA for the treatment of schizophrenia and bipolar disorder. Olanzapine is structurally similar to clozapine and quetiapine. The present research work is aimed at developing a Formulate and Evaluated of a Rapid disintegrating tablet dosage form of Olanzapine. Who have little or no access to water are also good candidates for Rapid disintegrating tablets of Direct Compression method was employed for blending of drug with polymers in the given ratio as a nine formulations. The prepared powder blends were then compressed into tablets using the necessary Superdisintegrants like CCS, CP, and SSG and Excipients. The tablets were evaluated for Weight variation, thickness, hardness, friability, Drug Content and Disintegrating Time (Sec) were subjected to a 40 minutes in vitro drug release studies (USP dissolution rate test apparatus II, 50 rpm, 370C ±0.50C) using phosphate buffer, pH 6.8 as a dissolution medium (900ml). The amount of Olanzapine released from the tablet formulations at different time intervals was estimated using a UV spectroscopy method. The formulations that showed a considerable retardation of the drug release are considered promising. Among the nine formulations, F5 formulation containing Drug to Crospovidone (CP) in ratio 1:0.25 is optimized based on its ability to till 40 mins of invitro dissolution time, and its % Cumulative Drug Release Of The 96.09% of dissolution study.
